Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder
2
1
1
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
7 treatments under study, led by Rituximab
Research Leaders
5 sponsors active, led by National Cancer Institute (NCI)
Related Conditions
Often studied with 7 related conditions
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
0.0%
0 terminated out of 2 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (2)
Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders
Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
Research Network
Common Treatments
- Rituximab1
- Biopsy1
- Computed Tomography1
- Allogeneic Lmp1lmp2specific Cytotoxic Tlymphocytes1
- Positron Emission Tomography1
Active Sponsors
- National Cancer Institute (NCI)2
- Genmab1
- Children's Oncology Group1
- AbbVie1
- Timothy Voorhees1
Top Investigators
Ohio State University Comprehensive Cancer Center
Children's Oncology Group
Related Conditions
- Recurrent Polymorphic Posttransplant Lymphoproliferative Disorder2
- Refractory Polymorphic Posttransplant Lymphoproliferative Disorder2
- Ebvrelated Posttransplant Lymphoproliferative Disorder2
- Recurrent Monomorphic Posttransplant Lymphoproliferative Disorder2
- Monomorphic Posttransplant Lymphoproliferative Disorder1